Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Orca Biosystems Inc. is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio has 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates a focused level of activity within the patent office for their current biotechnology filings.
The examination is taking place in 1 distinct art unit. BELYAVSKYI, MICHAIL A is identified as the busiest examiner, with 1 busiest examiner pending office action currently assigned. This 1 action is the only pending matter for the company's portfolio at this time. With 1 distinct examiner and 1 distinct art unit, the prosecution path is straightforward and centralized. The 1 pending office action represents the only current hurdle in the Biotechnology & Pharmaceuticals sector. Practitioners can focus their resources on 1 examiner to move the application forward and achieve the company's strategic goals for its intellectual property portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 64.0% | +28.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142513 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | BELYAVSKYI, MICHAIL A | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18142513 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Non-Final OA | — | Pending | May 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrca Biosystems Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Michail A Belyavskyi has the most, with 1 of Orca Biosystems Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.